Privia Health Group Inc

PRVA is in a Stage 2 advance with a steep Parabola continuation pattern, rising EMAs, and a persistent higher-high/higher-low structure confirming medium-term bullish bias. However, price is extended above the 9/21 EMAs with RSI and Options Score in overbought territory, signaling pullback risk. Execution should be deferred, stalking for pullbacks into the rising EMA support zone for an optimal entry.

• ↑Q1 revenue $862.9M (+12.8% YoY) and adjusted EBITDA $36.7M (+36.3%) highlight strong financial momentum.
• ↑Attributed lives grew 26.5% YoY to 1.6M and providers increased 13.6% to 5,535.
• ↓Weak business quality metrics signal potential operational and balance sheet vulnerabilities.